Bristol Myers and Celgene are being sued in an antitrust suit, alleging they used fraud, sham litigation, and reverse ...

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...

Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect ...

Celgene had a major pipeline setback in October when GED-0301 proved ineffective at treating Crohn's disease in a late-stage study. But sometimes such clinical failures happen.

Celgene thanked the woman who had the idea to use thalidomide as a treatment for multiple myeloma in its annual report, but says she isn't owed a dime for discovering the $2.2 billion-a-year ...

This time, Celgene has picked on the wrong victim, and if you read between the lines of Judge Faith Hochberg's ruling (which keeps the case alive by as thinly contrived a judicial thread as I've ...

Celgene funded more studies combining thalidomide with a treatment for myeloma, and it became the standard of care for the blood cancer. At first, Beth Wolmer had a warm relationship with the company.

Cancer-drug company Celgene Corp. said it will pay $7.2 billion for biotech company Receptos Inc. in a bid to move deeper into the multibillion-dollar market for autoimmune diseases.

Celgene just acquired immunotherapy biotech Juno Therapeutics in a $9 billion dollar deal. The deal will allow Celgene to compete in a space already occupied by Novartis and Gilead as they vie for ...

New Jersey-based Celgene will pay Juno approximately $1 billion, which includes the purchase of 9.1 million shares at $93 per share (Juno’s stock closed on Monday at $46.30 per share).

Cigna sued Bristol Myers Squibb on Tuesday, accusing the drugmaker of violating U.S. antitrust law by keeping generic ...